Cinctive Capital Management LP Sells 79,573 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cinctive Capital Management LP decreased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 194,386 shares of the biotechnology company's stock after selling 79,573 shares during the period. Cinctive Capital Management LP owned approximately 0.09% of BioCryst Pharmaceuticals worth $1,462,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in BCRX. Venturi Wealth Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $46,000. R Squared Ltd acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth about $48,000. KBC Group NV boosted its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after buying an additional 4,537 shares during the period. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $80,000. Finally, Quantinno Capital Management LP acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded up $0.30 during trading on Wednesday, hitting $6.77. 4,598,501 shares of the stock traded hands, compared to its average volume of 2,801,190. The company has a fifty day moving average price of $8.01 and a two-hundred day moving average price of $7.76. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The stock has a market cap of $1.41 billion, a P/E ratio of -11.10 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The firm's quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the company earned $0.28 earnings per share. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on BCRX shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Needham & Company LLC lifted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a report on Monday, January 13th. JMP Securities reissued a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush assumed coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $15.57.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.